Express Scripts Follows CVS In Dropping Humira From Formularies
Cigna’s Evernorth Continues To Make Moves To Boost Biosimilar Adalimumab In US
Executive Summary
Express Scripts has announced plans to drop branded Humira from formularies in the US next year, in favor of biosimilar adalimumab rivals. The move comes after a similar decision from fellow pharmacy benefit manager CVS Caremark earlier this year, which has already boosted biosimilars significantly.